Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ACTR 087/SEA BCMA - Cogent Biosciences/Seattle Genetics

Drug Profile

ACTR 087/SEA BCMA - Cogent Biosciences/Seattle Genetics

Alternative Names: ACTR 087/SEA BCMA; ACTR-BCMA; ACTR087 + SEA-BCMA; ACTR087 + SEA-BCMA combination therapy; SEA BCMA/ACTR 087

Latest Information Update: 04 Jul 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Unum Therapeutics
  • Class Antineoplastics; Gene therapies; Immunotherapies; Monoclonal antibodies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Immunostimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Multiple myeloma

Most Recent Events

  • 12 Jan 2021 Cogent Biosciences terminates licensing agreement with National University of Singapore and St. Jude Children’s Research Hospital for development of ACTR constructs
  • 05 Oct 2020 Unum Therapeutics is now called Cogent Biosciences
  • 12 Feb 2020 Discontinued - Phase-I for Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (Parenteral) (NCT03266692)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top